Name: Semiconductors to buy on dips, biotech to increase weighting…H2 strategy revealed | Lee Jae-gyu, SK Securities PB Deputy Manager [Focus Today's Stock]
Uploaded: 2026-06-29T11:30:14+00:00
Duration: 2140 s

Speakers

Lee Jae-kyu — PB Deputy Manager, SK Securities

Summary

SK Securities PB Deputy Manager Lee Jae-gyu presents his H2 strategy amid recent volatility. He believes KOSPI’s uptrend is intact and recommends buying semiconductor dips. Meanwhile, he sees a potential shift in KOSDAQ, with biotech emerging as the top sector due to narrowing decoupling with strong US biotech. He is also constructive on secondary batteries and deeply oversold entertainment/cosmetics names.

KOSPI trend not broken; equity weight should be maintained.
Semiconductors remain the leading sector; buy on dips but expect slower upside.
KOSDAQ’s repeated dead-cat bounce pattern may be changing; additional rebound likely.
Korean biotech is the top pick, driven by US biotech strength and China regulation benefits.
Secondary battery sector gets momentum from ESS, renewables, and EV sales recovery.
Entertainment and cosmetics stocks are near PBR bottom with potential institutional inflow.
Macro backdrop is stable with lower oil and bond yields, despite elevated KRW/USD.

Ideas

Lee Jae-kyu PB Deputy Manager, SK Securities 0:26

KOSPI uptrend intact, stay invested

KOSPI's uptrend is not broken despite recent pullback; overall trend remains intact, so there is no need to worry. Equity exposure should not be reduced aggressively. The market is likely to resume its uptrend with broad support.

Lee Jae-kyu PB Deputy Manager, SK Securities 2:04

Buy semiconductor dips, uptrend continues

Semiconductors remain the leading sector; the pattern of buying dips has repeatedly worked. Operating profits at Samsung Electronics and SK hynix are very high, so the positive trend will continue although upside may slow. If an investor does not own semiconductors, buying on pullbacks is correct.

Lee Jae-kyu PB Deputy Manager, SK Securities 2:53

KOSDAQ rebound likely, pattern shifting

KOSDAQ has been in a pattern of dead-cat bounces, but recent supply/demand data (foreign buying over the past two months) and today's resilience while semiconductor stocks rallied suggest a change. KOSDAQ is likely to see additional rebound, not just another upper shadow. The decoupling with heavy-tech selling and biotech holding up supports further gains.

Lee Jae-kyu PB Deputy Manager, SK Securities 17:00

Korean biotech top pick, gap narrowing

The Korean biotech and healthcare sector is the top pick within KOSDAQ. US biotech indices (XBI, NBI) are at all-time highs, while Korean biotech has decoupled and lagged. This gap will likely narrow, bringing foreign and institutional money. Additionally, US regulation on China’s CDMO, ADC, and dual-antibody firms will benefit Korean companies like LigaChem Bio, ABL Bio, and Orum Therapeutics, who have strong pipelines. Big-cap names like Samsung Biologics and Celltrion are globally profitable.

Lee Jae-kyu PB Deputy Manager, SK Securities 27:13

Entertainment, cosmetics near PBR bottom, rebound

Entertainment and cosmetics stocks have fallen to their PBR lower band and are showing signs of technical rebound. Institutions and foreign investors may start accumulating these deeply undervalued names. Although the sector ranks lower than biotech and semiconductors, investors who already hold these stocks could see additional upside.

Lee Jae-kyu PB Deputy Manager, SK Securities 31:17

Secondary batteries benefit from ESS, EV

The secondary battery sector is seeing positive momentum from energy storage systems (ESS), renewable energy expansion, rising lithium prices, and increasing global EV sales (including Tesla). While the ESS revenue share for companies like Samsung SDI is still small (15%), growing to 20-25% in H2 would be key. Overall, the sector is attractive after heavy sell-offs.

Semiconductors to buy on dips, biotech to increase weighting…H2 strategy revealed

Summary

Ideas

Up Next